ATE327753T1 - Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes - Google Patents

Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes

Info

Publication number
ATE327753T1
ATE327753T1 AT02742955T AT02742955T ATE327753T1 AT E327753 T1 ATE327753 T1 AT E327753T1 AT 02742955 T AT02742955 T AT 02742955T AT 02742955 T AT02742955 T AT 02742955T AT E327753 T1 ATE327753 T1 AT E327753T1
Authority
AT
Austria
Prior art keywords
ppar
diabetes
alpha
treatment
carboxylic acid
Prior art date
Application number
AT02742955T
Other languages
German (de)
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE327753T1 publication Critical patent/ATE327753T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02742955T 2001-05-15 2002-05-06 Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes ATE327753T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
ATE327753T1 true ATE327753T1 (de) 2006-06-15

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02742955T ATE327753T1 (de) 2001-05-15 2002-05-06 Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes

Country Status (38)

Country Link
US (1) US6642389B2 (enExample)
EP (1) EP1392295B1 (enExample)
JP (2) JP4330883B2 (enExample)
KR (1) KR100654516B1 (enExample)
CN (1) CN100356917C (enExample)
AR (1) AR035892A1 (enExample)
AT (1) ATE327753T1 (enExample)
AU (1) AU2002342244B2 (enExample)
BG (1) BG66316B1 (enExample)
BR (1) BRPI0209821B1 (enExample)
CA (1) CA2445145C (enExample)
CY (1) CY1105160T1 (enExample)
CZ (1) CZ20033037A3 (enExample)
DE (1) DE60211891T2 (enExample)
DK (1) DK1392295T3 (enExample)
EC (1) ECSP034848A (enExample)
EG (1) EG25755A (enExample)
ES (1) ES2264482T3 (enExample)
GT (1) GT200200085A (enExample)
HR (1) HRP20030889B1 (enExample)
HU (1) HU230224B1 (enExample)
IL (2) IL158589A0 (enExample)
JO (1) JO2282B1 (enExample)
MA (1) MA27025A1 (enExample)
ME (1) ME01310B (enExample)
MX (1) MXPA03010435A (enExample)
MY (1) MY136761A (enExample)
NO (1) NO333833B1 (enExample)
NZ (1) NZ529033A (enExample)
PA (1) PA8544901A1 (enExample)
PE (1) PE20021152A1 (enExample)
PL (1) PL208074B1 (enExample)
PT (1) PT1392295E (enExample)
RU (1) RU2278859C2 (enExample)
SI (1) SI1392295T1 (enExample)
SK (1) SK287842B6 (enExample)
WO (1) WO2002092084A1 (enExample)
ZA (1) ZA200308538B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
WO2001090087A1 (en) * 2000-05-26 2001-11-29 Nippon Shinyaku Co., Ltd. Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
CZ20033037A3 (cs) * 2001-05-15 2004-06-16 F. Hoffmann-La Roche Ag Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
DE60325768D1 (de) * 2002-11-15 2009-02-26 Cadila Healthcare Ltd Substituierte aralkyl verbindungen
AU2003292030B2 (en) * 2002-11-25 2007-01-04 F. Hoffmann-La Roche Ag Indolyl derivatives
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1682508A1 (en) * 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
KR100849352B1 (ko) 2003-11-05 2008-07-29 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
PL1756096T3 (pl) 2004-05-03 2010-01-29 Hoffmann La Roche Pochodne indolilowe jako modulatory wątrobowych receptorów X
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
PT2100604E (pt) * 2008-03-10 2012-07-24 Nestec Sa Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
US9659037B2 (en) 2008-12-23 2017-05-23 Roche Diabetes Care, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
KR20110105798A (ko) * 2009-01-23 2011-09-27 에프. 호프만-라 로슈 아게 알레글리타자르를 포함하는 약학 조성물
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
DK2585452T3 (en) 2009-12-07 2015-10-12 Hoffmann La Roche PROCESS FOR THE PREPARATION OF propionic
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
EP2895469B1 (en) * 2012-09-12 2017-10-18 F. Hoffmann-La Roche AG Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
CN109588042A (zh) 2015-11-18 2019-04-05 豪夫迈·罗氏有限公司 用于治疗糖尿病肾病的阿格列扎
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4384507A4 (en) * 2021-08-13 2025-06-18 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
CN120091812A (zh) 2022-11-08 2025-06-03 基恩菲特公司 用于治疗肝衰竭的PPARα/γ激动剂
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
ATE207470T1 (de) 1992-07-03 2001-11-15 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
EP0903343B1 (en) 1997-09-19 2003-05-28 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1078923T3 (da) 1999-08-02 2006-07-10 Hoffmann La Roche Fremgangsmåde til fremstilling af benzothiophenderivater
MXPA03001558A (es) * 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.
CZ20033037A3 (cs) * 2001-05-15 2004-06-16 F. Hoffmann-La Roche Ag Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu

Also Published As

Publication number Publication date
ZA200308538B (en) 2005-04-26
EP1392295B1 (en) 2006-05-31
BG66316B1 (bg) 2013-04-30
DE60211891D1 (de) 2006-07-06
ES2264482T3 (es) 2007-01-01
US6642389B2 (en) 2003-11-04
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
MXPA03010435A (es) 2004-03-09
PT1392295E (pt) 2006-09-29
NZ529033A (en) 2005-06-24
JO2282B1 (en) 2005-09-12
WO2002092084A1 (en) 2002-11-21
DK1392295T3 (da) 2006-10-02
JP4330883B2 (ja) 2009-09-16
BG108362A (bg) 2005-03-31
AR035892A1 (es) 2004-07-21
ME01310B (me) 2011-10-10
AU2002342244B2 (en) 2005-06-16
SK287842B6 (sk) 2011-12-05
CA2445145C (en) 2008-10-14
KR100654516B1 (ko) 2006-12-05
HUP0400992A3 (en) 2007-11-28
PE20021152A1 (es) 2003-02-07
BRPI0209821B1 (pt) 2016-09-27
KR20030096397A (ko) 2003-12-24
HRP20030889B1 (hr) 2011-10-31
PL208074B1 (pl) 2011-03-31
DE60211891T2 (de) 2007-05-24
US20030055265A1 (en) 2003-03-20
CN100356917C (zh) 2007-12-26
SI1392295T1 (sl) 2006-10-31
PA8544901A1 (es) 2003-01-24
GT200200085A (es) 2003-01-16
SK13852003A3 (en) 2004-10-05
MA27025A1 (fr) 2004-12-20
NO20035086L (no) 2003-11-14
CY1105160T1 (el) 2009-11-04
EP1392295A1 (en) 2004-03-03
IL158589A (en) 2010-11-30
HRP20030889A2 (en) 2005-08-31
NO333833B1 (no) 2013-09-30
HU230224B1 (hu) 2015-10-28
JP2009138011A (ja) 2009-06-25
IL158589A0 (en) 2004-05-12
HUP0400992A2 (hu) 2004-08-30
CZ20033037A3 (cs) 2004-06-16
EG25755A (en) 2012-06-26
BR0209821A (pt) 2004-06-01
NO20035086D0 (no) 2003-11-14
RU2003134150A (ru) 2005-06-10
CA2445145A1 (en) 2002-11-21
ECSP034848A (es) 2003-12-24
HK1067534A1 (en) 2005-04-15
CN1509173A (zh) 2004-06-30
MY136761A (en) 2008-11-28
JP2004529174A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
ATE327753T1 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
ATE524173T1 (de) Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
DE60327745D1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60012774D1 (de) Zusammensetzungen mit hydroxyeicosatetraensäure derivate und verfahren zur verwendung zur behandlung des trockenen auges
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE365159T1 (de) 3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE386013T1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
DE60237594D1 (de) Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
ATE550327T1 (de) Bicyclische iminosäurederivate zur behandlung von (unter anderem) erkrankungen des bewegungsapparates
DE602004015272D1 (de) Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
DE60319082D1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392295

Country of ref document: EP